Monitoring for VOD: Best practice from University Hospital Birmingham
Dr Manos Nikolousis describes the monitoring practice at his trust, as well as the value of a 24-hour blood and marrow transplantation chart in maintaining best practice.
Risk assessment and monitoring
ADVERSE EVENTS REPORTING
Adverse events should be reported. Reporting forms and information for the UK can be found at: https://yellowcard.mhra.gov.uk/
For Ireland, reporting forms and information can be found at: www.hpra.ie
Adverse events should also be reported to Jazz Pharmaceuticals at: AEreporting@jazzpharma.com
Defitelio® is indicated for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstruction syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy. It is indicated in adults and in adolescents, children and infants over 1 month of age.